COVID-19 and gynecological cancers: Asia and Oceania Federation of Obstetrics and Gynecology oncology committee opinion.
AOFOG opinion
COVID-19
gynecological cancer
Journal
The journal of obstetrics and gynaecology research
ISSN: 1447-0756
Titre abrégé: J Obstet Gynaecol Res
Pays: Australia
ID NLM: 9612761
Informations de publication
Date de publication:
May 2021
May 2021
Historique:
received:
11
09
2020
accepted:
13
11
2020
pubmed:
3
3
2021
medline:
22
6
2021
entrez:
2
3
2021
Statut:
ppublish
Résumé
Since the outbreak of COVID-19, there have already been over 26 million people being infected and it is expected that the pandemic will not end in near future. Not only the daily activities and lifestyles of individuals have been affected, the medical practice has also been modified to cope with this emergency catastrophe. In particular, the cancer services have faced an unprecedented challenge. While the services may have been cut by the national authorities or hospitals due to shortage of manpower and resources, the medical need of cancer patients has increased. Cancer patients who are receiving active treatment may develop various kinds of complications especially immunosuppression from chemotherapy, and they and their carers will need additional protection against COVID-19. Besides, there is also evidence that cancer patients are more prone to deteriorate from COVID-19 if they contract the viral infection. Therefore, it is crucial to establish guidelines so that healthcare providers can triage their resources to take care of the most needed patients, reduce less important hospitalization and visit, and to avoid potential complications from treatment. The Asia and Oceania Federation of Obstetrics and Gynecology (AOFOG) hereby issued this opinion statement on the management of gynecological cancer patients during the COVID-19.
Identifiants
pubmed: 33650217
doi: 10.1111/jog.14579
pmc: PMC8013896
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1643-1650Informations de copyright
© 2021 Japan Society of Obstetrics and Gynecology.
Références
Ann Oncol. 2020 Jul;31(7):894-901
pubmed: 32224151
Cancer Discov. 2020 Jun;10(6):783-791
pubmed: 32345594
Lancet. 2020 Jun 20;395(10241):1919-1926
pubmed: 32473682
J Gynecol Oncol. 2020 Jul;31(4):e69
pubmed: 32406213
Lancet Oncol. 2020 Jul;21(7):893-903
pubmed: 32479790
Eur J Surg Oncol. 2020 Jun;46(6):1182-1183
pubmed: 32359918
Int J Gynecol Cancer. 2020 May;30(5):561-563
pubmed: 32221023
JAMA. 2020 May 12;323(18):1775-1776
pubmed: 32203977
J Gynecol Obstet Hum Reprod. 2020 Jun;49(6):101729
pubmed: 32247066
J Geriatr Oncol. 2020 Jun;11(5):753-760
pubmed: 32340908
Gynecol Oncol. 2020 Jul;158(1):16-24
pubmed: 32386911
J Gynecol Oncol. 2020 May;31(3):e59
pubmed: 32242340
Lancet Oncol. 2019 May;20(5):636-648
pubmed: 30948273
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Lancet. 2020 Jun 27;395(10242):1973-1987
pubmed: 32497510
J Clin Oncol. 2020 Apr 10;38(11):1164-1174
pubmed: 32073956